Survival in Small-Cell Lung Cancer Improved With Cytotoxic Add-On to Immunotherapy

By News Health
6 hours Ago

(MedPage Today) — CHICAGO — Patients with extensive-stage small-cell lung cancer (SCLC) lived significantly longer with the addition of cytotoxic agent lurbinectedin (Zepzelca) to maintenance immunotherapy, a large randomized trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115728

Author :

Publish date : 2025-05-22 21:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

'My son could so easily have been another Nottingham killer'

FDA Panel Recommends Monovalent COVID Vaccine for Next Season

Study Links GLP-1 Drugs to Lower Cancer Risk

FDA Chief Defends Job Cuts, COVID Booster Policy at Senate Hearing

Prasugrel Strategy Rolls Short DAPT and De-Escalation Into One

FDA Approves Roflumilast Foam for Scalp, Body Psoriasis